Triatomic Management’s BioNTech BNTX Stock Holding History

Triatomic Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,636	Closed	-$612K	–	40
2023 Q3	$612K	Hold	5,636	–	–	0.42%	32
2023 Q2	$608K	Hold	5,636	–	–	0.62%	31
2023 Q1	$702K	Hold	5,636	–	–	0.47%	32
2022 Q4	$847K	Hold	5,636	–	–	0.71%	22
2022 Q3	$760K	Hold	5,636	–	–	0.44%	29
2022 Q2	$840K	Hold	5,636	–	–	0.77%	26
2022 Q1	$961K	Buy	+5,636	New	+$947K	0.78%	26

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Triatomic Management's BNTX Position: Q4 2023 in Review

Triatomic Management sold out of BioNTech (BNTX) in Q4 2023, closing a stake of 5,636 shares — an estimated $612K sold.

Triatomic Management first reported a position in BNTX in Q1 2022 and held it in 7 quarters. The position peaked at $961K in Q1 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q4 2023.

Triatomic Management reported no remaining BioNTech position as of Q4 2023 after selling out during the quarter.
Triatomic Management sold 5,636 BioNTech shares in Q4 2023, an estimated $612K.
Triatomic Management first reported a position in BioNTech in Q1 2022 and held it in 7 quarters.
Triatomic Management's BioNTech position peaked at $961K in Q1 2022.
282 funds tracked by Wall St. Rank held BioNTech as of Q4 2023.

Based on Triatomic Management's 13F filing for Q4 2023, filed 13 Feb 2024.